Top Page
Oncotelic Therapeutics
(OTC:OTLC)
Oncotelic Therapeutics (OTLC) vs. SPDR S&P 500 ETF (SPY)
Oncotelic Therapeutics Business Overview & Revenue Model
Oncotelic Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 70.00K | 0.00 | 0.00 | 1.74M |
| Gross Profit | 0.00 | 0.00 | 70.00K | -12.84K | -61.51K | 1.74M |
| EBITDA | -863.01K | -3.55M | -7.16M | -5.60M | -9.06M | -7.61M |
| Net Income | -1.67M | -4.52B | -7.90M | 17.82M | -11.39M | -11.50M |
Balance Sheet | ||||||
| Total Assets | 28.16M | 26.68M | 30.01M | 36.12M | 23.61M | 23.66M |
| Cash, Cash Equivalents and Short-Term Investments | 409.00K | 86.13K | 170.41K | 241.45K | 568.77K | 474.02K |
| Total Debt | 17.41M | 13.09M | 12.57M | 11.26M | 8.99M | 5.43M |
| Total Liabilities | 20.08M | 19.20M | 18.40M | 16.92M | 15.45M | 11.18M |
| Stockholders Equity | 9.05M | 8.25M | 12.13M | 19.41M | 7.96M | 11.77M |
Cash Flow | ||||||
| Free Cash Flow | -704.01K | -740.27K | -1.32M | -1.45M | -4.43M | -2.81M |
| Operating Cash Flow | -704.01K | -740.27K | -1.32M | -1.45M | -4.43M | -2.81M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 964.00K | 656.00K | 1.25M | 1.13M | 4.53M | 3.22M |
Oncotelic Therapeutics Technical Analysis
Oncotelic Therapeutics Risk Analysis
Oncotelic Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $56.17M | -6.41 | -13.15% | ― | ― | 45.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $35.23M | -1.75 | -104.58% | ― | ― | 1.18% | |
48 Neutral | $44.84M | -1.11 | ― | ― | -14.92% | 72.81% | |
46 Neutral | $34.17M | -18.29 | -38.38% | ― | ― | 65.22% | |
44 Neutral | $89.25M | -2.61 | -2691.06% | ― | ― | 44.50% | |
40 Underperform | $12.97M | -0.42 | -526.36% | ― | ― | -2.46% |
Oncotelic Therapeutics Corporate Events
On January 23, 2026, Oncotelic Therapeutics secured $398,333 in convertible debt from Mast Hill Fund, issuing a one-year, 10% secured note convertible at $0.07 per share, together with 1,422,613 warrants at $0.15, and restricted the use of proceeds to working capital. The agreement, backed by most company assets and paired with registration rights for the conversion shares and warrants, underscores a leverage-heavy financing that could dilute equity while bolstering near-term liquidity for ongoing oncology programs.
The most recent analyst rating on (OTLC) stock is a Hold with a $0.07 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.
On January 22, 2026, Oncotelic Therapeutics, Inc. entered into a restricted stock agreement with chief executive officer Dr. Vuong Trieu that ties his equity compensation to specific capital-structure improvement milestones. The company will issue up to 26,512 shares of Series A Preferred Stock, each convertible into 1,000 common shares, with vesting contingent on four milestones, including conversion of $2.175 million in 2023 notes into new 2025 Units, securing additional convertible debt from Mast Hill Fund alongside achieving a $45 million market capitalization, converting about $3.3 million of related-party short-term loans into 2025 Units, and repaying $2.175 million in notes underlying those units. Dr. Trieu has already met the first milestone and will receive 4,426 preferred shares, with a further 22,086 shares vesting in three equal tranches as later milestones are reached; the total potential issuance represents about 4.99% of current common shares, structured with anti-dilution protection to maintain at least 1.663% per milestone, underscoring a strong incentive alignment around balance-sheet repair and debt restructuring that could materially affect existing shareholders and the company’s financing profile.
The most recent analyst rating on (OTLC) stock is a Hold with a $0.07 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.
On January 6, 2026, Oncotelic Therapeutics, Inc. announced amendments to an independent contractor agreement with Jefferson Capital Ventures, LLC, originally dated August 6, 2025, and to a restricted stock award agreement dated November 17, 2025, with its CEO, Dr. Vuong Trieu, both tied to the achievement of corporate milestones. The company lowered the market capitalization threshold for the first milestone from $100 million to $45 million, affecting Jefferson’s restricted common stock awards and Dr. Trieu’s restricted preferred stock awards, while leaving all other milestone terms unchanged; this move is intended to support execution of Oncotelic’s ongoing initiatives, including using its equity line with Mast Hills, advancing future financing arrangements, and working toward uplisting its stock to a nationally recognized exchange, thereby potentially improving its capital access and strategic positioning.
The most recent analyst rating on (OTLC) stock is a Hold with a $0.08 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.
On December 31, 2025, Oncotelic Therapeutics, Inc. amended its independent contractor agreement with Jefferson Capital Ventures, LLC, changing the threshold for Jefferson to earn restricted stock awards from a market capitalization milestone of $100 million on a single trading day’s close to $45 million on a single trading day’s close, while leaving all other terms unchanged. The revised milestone is intended to support Oncotelic’s ongoing initiatives to activate its equity line with Mast Hills, advance future financing through AGP, and work with Sichenzia, Ross and Ferrell on a potential uplisting to a major stock exchange, signaling a strategic effort to make incentive-based equity awards more attainable and to reinforce the company’s capital markets strategy and corporate growth objectives.
The most recent analyst rating on (OTLC) stock is a Hold with a $0.08 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.
On December 31, 2025, Oncotelic Therapeutics, Inc. completed the third and final tranche of a private offering, issuing 44 units to 22 accredited investors under subscription agreements, while two prior investors holding a total of seven units from a 2023 private placement memorandum did not participate. Each unit in the offering consists of a $25,000 note bearing 12% annual interest maturing two years after the final closing, convertible into either 250,000 shares of Oncotelic common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc. common stock at $1.00 per share, along with associated warrants to purchase additional shares of either Oncotelic or EdgePoint at preset prices, all subject to anti-dilution protections. As part of the transaction, the company treated existing 2023 notes as paid off and rolled investor contributions into the new notes, extended the life of previously issued 2023 warrants by two years, and granted investors the option to convert EdgePoint shareholdings into Oncotelic stock at an exchange rate of 10 Oncotelic shares for each EdgePoint share, potentially aligning interests more directly with the parent company; it also entered into a registration rights agreement covering the common shares issued and issuable under the financing, signaling a move to enhance liquidity and investor protections for these securities. The securities were issued under an exemption from Securities Act registration requirements, reinforcing the company’s reliance on private capital markets to support its capital structure and strategic relationship with its AI-focused subsidiary.
The most recent analyst rating on (OTLC) stock is a Hold with a $0.08 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.
On December 23, 2025, Oncotelic Therapeutics, Inc. completed subscription agreements with 21 accredited investors for 32 units in a private offering of up to 500 units, each consisting of a $25,000, 12% two-year note convertible into either Oncotelic or EdgePoint AI stock, along with associated warrants in both companies subject to anti-dilution protections. The transaction, which also refinances the company’s 2023 PPM note and extends prior warrant expirations by two years while allowing investors to swap EdgePoint shares into Oncotelic stock, enhances capital flexibility and investor optionality and is supported by a registration rights agreement for underlying Oncotelic shares, potentially strengthening the company’s financing position without relying on public registration at this stage.
The most recent analyst rating on (OTLC) stock is a Hold with a $0.08 price target. To see the full list of analyst forecasts on Oncotelic Therapeutics stock, see the OTLC Stock Forecast page.
On December 22, 2025, Oncotelic Therapeutics, Inc. announced that it had opened access to PDAOAI, its proprietary evidence-interrogation platform built to extract biologically meaningful signals from large, complex biomedical datasets without the need to train bespoke large language models on proprietary data. The company also made available to researchers a comprehensive TGF-β literature corpus of more than 125,000 PubMed abstracts via a dedicated Discord research channel, a move that could broaden scientific engagement with its technology and strengthen its position in data-driven oncology and translational research ecosystems.
On December 4, 2025, Oncotelic Therapeutics completed a subscription agreement with accredited investors, issuing 11 units as part of a larger offering of up to 500 units. Each unit includes a note convertible into shares of Oncotelic or its subsidiary EdgePoint AI, along with warrants to purchase additional shares. This strategic financial move aims to enhance investment flexibility and extend the terms of previous warrants, potentially impacting the company’s financial structure and investor relations.